WebMar 13, 2024 · China will add 111 drugs to its national medical reimbursement list this year, with a focus on including treatments for infections, COVID-19 drugs and advanced … WebJan 3, 2024 · The reference medicines were camrelizumab (vs sintilimab), crizotinib (vs alectinib), lapatinib (vs pyrotinib) and icotinib and gefitinib (vs erlotinib). The information for all 16 successfully negotiated TAMs is presented in Additional file 1: Online Appendix 1.
China’s latest NRDL update continues to exclude foreign PD-1 …
WebMar 2, 2024 · A new national reimbursement drug list took effect on March 1 in a major boost to relieving the financial burden on Chinese patients and increasing … WebJan 22, 2024 · The NRDL is a list of drugs that are authorized by central government agencies for reimbursement. The government will pay back some of the expenses only … china ul844 led brands
National Reimbursement Drug List Negotiation in …
WebNov 12, 2024 · BEIJING -- China is expected to release a renewed catalog of drugs covered by its national medical insurance system in late November, the National Healthcare Security Administration (NHSA) said Friday. WebDec 20, 2024 · The 2024 NRDL, which will be implemented on 1 January 2024, now includes 2,860 drugs, of which 1,486 are ‘Western’-made medicines, and 1,374 Chinese-patented medicines. The NRDL includes 892 traditional Chinese medicines (TCMs). Pricing data for individual drugs were not released. Imported PD-1/L1 inhibitors excluded… yet … WebJan 4, 2024 · In particular, a Chinese biopharma, RemeGen, made its NRDL debut and scored two major wins with its SLE drug Telitacicept and gastric cancer ADC Disitamab Vedotin. The latter was out licensed to Seagen ex-Asia for 2.8 billion US dollars earlier this year, a record-breaking deal for China’s biopharma industry. china ultrasonic horn design software